Novo Nordisk A/S’s blockbuster weight-loss drug Wegovy received Food and Drug Administration approval to treat a serious form of liver disease, beating rival Eli Lilly & Co. to the US market for the ...

Novo Nordisk’s obesity drug Wegovy was cleared by U.S. regulators to treat an increasingly common liver disease, MASH.

Novo Nordisk said on Friday the U.S. Food and Drug Administration had granted accelerated approval for its weight-loss drug ...

Novo Nordisk's weight-loss drug Wegovy has been approved to treat a common type of liver disease, the Food and Drug ...

Novo Nordisks stock has tumbled from record highs after slashing its 2025 outlook, as fierce competition, leadership changes, ...

C’était l’histoire dont tout le monde parlait. En 2024, Novo Nordisk, grâce à ses traitements révolutionnaires contre l’obésité, s’imposait comme la première capitalisation boursière d’Europe, ...

As new therapies for obesity enter the market, biopharmaceutical companies will need to tune commercial strategies to win ...

WeightWatchers is now only offering Wegovy while other telehealth providers defiantly hang on to compounded alternatives.

Monday, after the company known as WeightWatchers reported better-than-expected second-quarter revenue amid robust demand for GLP-1 obesity treatments. WW, which emerged from bankruptcy on June 24, ...

JOANNA Higgenbottom spent almost $800 (£600) each month on takeaways, before Mounjaro helped her shed 23st. The 60-year-old ...

Scientists have uncovered a hidden molecule in DNA that helps control fat storage, offering hope for a new kind of obesity ...

After a rough reception and a rebrand to support users of GLP-1 drugs, Peoplehood is selling its assets to WeightWatchers.